Comparison

5-amino-1MQ vs
MOTS-c

They are different kinds of molecules, with different research records. Here is what can be said from the sources reviewed, and what still needs checking.

Short answerCompound research · 6 min read · Updated 21 Nov 2026

5-amino-1MQ is 5-amino-1-methylquinolinium, a small-molecule quinolinium compound, not a peptide; MOTS-c is a 16-amino-acid peptide encoded by mitochondrial 12S rRNA. Both have cell and animal studies (T4, T3). We found no published study that gave either to people (PubMed and ClinicalTrials.gov, 21 November 2026); one registered MOTS-c trial has no posted results.

Key takeaways

  • 5-amino-1MQ is a small molecule; MOTS-c is a peptide.
  • 5-amino-1MQ’s published studies are in cells and mice; they are not evidence of an effect in people.
  • Human studies of MOTS-c measured the body’s own levels; we found no published study that gave it to people (PubMed and ClinicalTrials.gov, 21 November 2026).
  • FDA staff recommended against adding MOTS-c to the 503A bulks list; HHS records that its advisory committee voted in favour, and its October 2026 draft policy, which “is not binding”, names MOTS-c. FDA’s 503A nominations list has no entry for 5-amino-1MQ.
  • WADA’s 2026 and 2027 Lists name MOTS-c in S4.4.1, prohibited at all times; neither names 5-amino-1MQ, and for a substance it does not list WADA says “please verify its status with your Anti-Doping Organization”.

015-amino-1MQ vs MOTS-c in one table

Comparison based on the records cited below, checked on 21 November 2026. A blank in the evidence record is not a verdict about what future research may find.

Question5-amino-1MQMOTS-c
Identity5-amino-1-methylquinolinium; a small molecule, not a peptide. PubChem lists formula C10H11N2+.A 16-amino-acid peptide encoded in mitochondrial 12S rRNA; sequence MRWQEMGYIFYPRKLR.
Evidence described hereCell studies (T4) and mouse studies (T3): 9 mice per cohort in a 2018 paper, 8 per group in a 2024 paper. Not evidence of an effect in people.Cell (T4) and animal (T3) studies, not evidence of an effect in people; human studies measured the body’s own MOTS-c (T2).
Human dataWe found no study that gave it to people (PubMed with its other names and human terms, and ClinicalTrials.gov, 21 Nov 2026).We found no published study that gave it to people (PubMed and ClinicalTrials.gov, 21 Nov 2026); registered trial NCT07505745 has no posted results. Human studies measured the body’s own levels.
United States regulatory recordsDrugs@FDA (through openFDA, data to 20 Nov 2026) lists no product with it as an active ingredient, and FDA’s 503A nominations list (updated 14 May 2026) has no entry for it (searched 21 Nov 2026). We draw no legal conclusion of our own.FDA staff recommended against adding MOTS-c to the 503A bulks list (July 2026 briefing); HHS records that its advisory committee voted in favour of both forms. HHS’s October 2026 draft policy, which “is not binding”, names MOTS-c.
United Kingdom and AustraliaUK: the emc medicines database returned no results for 5-amino-1MQ or methylquinolinium (21 Nov 2026); it is not the full UK register. Australia: the Poisons Standard October 2026 has no entry for 5-amino-1-methylquinolinium or methylquinolinium (searched 21 Nov 2026); we draw no scheduling conclusion of our own.UK: the emc database returned no results for MOTS-c (21 Nov 2026); it is not the full UK register. Australia: The TGA says “many products promoted online are unapproved therapeutic goods and may be unlawful to import, supply or advertise. Using unapproved peptide products can pose serious health risks.” MOTS-c has no entry by name in the Poisons Standard October 2026; we draw no scheduling conclusion of our own.
WADA sport statusNot named on the 2026 or 2027 List. For a substance it does not list, WADA says “please verify its status with your Anti-Doping Organization”; we draw no sport-status conclusion of our own.Named in S4.4.1 (activators of AMPK) on the 2026 and 2027 Lists; S4 substances are prohibited at all times.

02What differs between the molecules?

Left: a small molecule built on a quinolinium ring system. Right: a chain of 16 amino acids. Drawn to show the difference in kind, not to scale.
Molecule class

Small molecule

PubChem identifies 5-amino-1-methylquinolinium as a charged quinolinium compound. It is not a chain of amino acids.

Molecule class

Peptide

MOTS-c is a 16-amino-acid mitochondrial peptide. Its sequence and molecular identity do not make it the same kind of molecule as 5-amino-1MQ.

The comparison stops at identity and the evidence records. The cited material does not establish that the compounds have equivalent effects, risks, or uses. It also does not support a “which is better” answer.

When reading studies about either compound, start with what was actually tested: the molecule, model, and outcome. A result in a cell or animal model is not a result in people. A study of naturally occurring MOTS-c levels is also different from a study that administers MOTS-c. These distinctions matter before comparing evidence tiers or drawing conclusions about human effects.

For 5-amino-1MQ, the published work is in cells and mice. A 2018 paper examined it as an inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT) in cell assays and in mice fed a high-fat diet, 9 per cohort; a 2024 paper used the same kind of mouse model, 8 per group, and its authors declared competing interests. Both are T4 and T3 work, not evidence of an effect in people.

For MOTS-c, cell and animal research is separate from human observations of naturally occurring levels, which do not test what happens when MOTS-c is given. We found no published study that gave either compound to people (21 November 2026), so these records cannot compare the two in people.

If you are checking a MOTS-c report, the next practical question is what the report says about identity and purity. See how to read a COA, and the MOTS-c research guide for the compound-specific evidence record.

03What do the regulatory and sport records say?

Regulatory records

Read the scope

An FDA compounding record addresses its stated compounding framework. It does not by itself answer every legal question about a compound or a person’s circumstances.

Anti-doping

Read the List text

MOTS-c is named in the 2026 WADA List. For 5-amino-1MQ, absence by name is not a ruling on how the List applies; WADA directs readers to their anti-doping organization.

For MOTS-c in the United States, FDA’s July 2026 briefing says the nomination was withdrawn and that FDA evaluated MOTS-c at its own discretion; FDA staff recommended against adding it to the 503A bulks list, and HHS records that its advisory committee voted in favour of both forms. HHS’s October 2026 policy names MOTS-c; the Federal Register notice calls it a draft that “is not binding”.

For Australia, the October 2026 Poisons Standard does not name MOTS-c. We found no TGA statement applying any of its group entries to MOTS-c, and we draw no scheduling conclusion of our own. For the UK, the cited searches did not find a marketing authorisation or a UK law naming MOTS-c. These are limited document checks, not advice about individual conduct.

Sport status is a separate question from a country’s regulatory status. MOTS-c is explicitly named in the 2026 WADA List. For 5-amino-1MQ, the List text checked does not name the compound, but that search result is not a ruling that it is permitted. WADA itself advises readers to verify an unnamed substance with their anti-doping organization.

04What do the records establish—and what remains open?

Identity

Different molecule classes

One is a small molecule; the other is a peptide.

Evidence

Same gap in people

Both have cell and animal studies; we found no published study that gave either to people.

Status

Different records

Compounding and anti-doping records must be read in their own scope.

  • Whether the cell and mouse findings for 5-amino-1MQ say anything about people: we found no study that tested it in people (21 November 2026).
  • What registered MOTS-c trial NCT07505745 will report: no results were posted as of 21 November 2026.
  • Whether the two compounds would differ in any human outcome. The cited evidence does not compare them in people.
  • How a regulator or anti-doping organization would apply its rules to a specific person, product, or circumstance.

In short, the reliable comparison is about identity, the evidence currently described, and the scope of the records—not which compound is more effective. New human research or a change to a regulatory list could alter parts of this comparison, so check the dated primary records for decisions that matter to you.

This is a plain-English summary of the records cited here, checked on 21 November 2026. It is not legal or medical advice.

RefSources

  1. PubChem. 5-Amino-1-methylquinolinium, CID 950107. Compound record, accessed 21 November 2026. pubchem.ncbi.nlm.nih.gov/compound/950107
  2. Neelakantan H, Vance V, Wetzel MD, et al. [NNMT inhibitor study in cells and diet-induced obese mice.] Biochemical Pharmacology, 2018;147:141–152. PMID 29155147; full text PMC5826726 read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/29155147/
  3. Babula JJ, Bui D, Stevenson HL, Watowich SJ, Neelakantan H. [NNMT inhibitor study in diet-induced obese mice.] Diabetes, Obesity and Metabolism, 2024;26(11):5272–5282. PMID 39161060; author manuscript PMC11622326 read 21 Nov 2026. onlinelibrary.wiley.com/doi/10.1111/dom.15879
  4. U.S. Food and Drug Administration. Drugs@FDA data through the openFDA API (last updated 20 Nov 2026): no product with 5-amino-1-methylquinolinium as an active ingredient. Database query, 21 Nov 2026. api.fda.gov/drug/drugsfda.json?search=products.active_ingred…
  5. U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A (categories 1 to 3). List updated 14 May 2026; read 21 Nov 2026. www.fda.gov/media/94155/download
  6. National Center for Biotechnology Information. PubChem compound record: 5-amino-1-methylquinolinium. Chemical database record. pubchem.ncbi.nlm.nih.gov/compound/5-Amino-1-methylquinoliniu…
  7. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327). Federal Register of Legislation, commenced 1 Oct 2026; text searched 21 Nov 2026 for methylquinolinium and 5-amino-1-methylquinolinium. www.legislation.gov.au/F2026L01327/latest/text
  8. PubMed search: 5-amino-1-methylquinolinium, 5A1MQ or 5-amino-1MQ with human terms: 3 records, cell, tissue and mouse work, none giving it to people; ClinicalTrials.gov: no record. Database searches, 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/?term=%28%225-amino-1-methylquinolin…
  9. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: MOTS-c-related bulk drug substances. Advisory committee briefing, 2026 (PDF pp. 7, 9, 29, 31, 33); read 21 Nov 2026. www.fda.gov/media/193347/download
  10. Reynolds JC, Lai RW, Woodhead JST, et al. [MOTS-c in mice of different ages, and natural MOTS-c levels in exercising men.] Nat Commun, 2021;12(1):470. PMID 33473109; full text PMC7817689 read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/33473109/
  11. Lee C, Zeng J, Drew BG, et al. [Description of MOTS-c, with cell and mouse experiments on metabolism.] Cell Metab, 2015;21(3):443–454. PMID 25738459. pubmed.ncbi.nlm.nih.gov/25738459/
  12. PubMed search: MOTS-c names with randomisation, placebo, administration and human terms, no publication-type filter: 13 records, none giving MOTS-c to people (cell, animal and level-measurement studies, and reviews). Database search, 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/?term=%28%22MOTS-c%22%5Btiab%5D%20OR…
  13. ClinicalTrials.gov. NCT07505745 [registered MOTS-c trial: eligibility and status]. Registry record read through the ClinicalTrials.gov API, 21 Nov 2026; last update posted 1 Apr 2026; no results posted. clinicaltrials.gov/study/NCT07505745
  14. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances (draft), Appendix B. Read on the Internet Archive capture of 15 Nov 2026, the newest readable one (hhs.gov returned 403 to our tools). web.archive.org/web/20261115103435/https://www.hhs.gov/sites…
  15. U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register notice, 91 FR 68526, 30 October 2026. www.federalregister.gov/documents/2026/10/30/2026-22192/enfo…
  16. Therapeutic Goods Administration. Peptide products. Topic page, last updated 23 Sep 2026; read on the Internet Archive capture of 5 Nov 2026, the newest (tga.gov.au did not respond to our tools). web.archive.org/web/20261105200754/https://www.tga.gov.au/re…
  17. Electronic medicines compendium (emc). Search for MOTS-c: “No search results” (control search, somatropin: 21 results). Database search, 21 Nov 2026. www.medicines.org.uk/emc/search?q=MOTS-c
  18. World Anti-Doping Agency. Prohibited List 2026. International Standard, in force 1 January 2026; read 21 Nov 2026. www.wada-ama.org/sites/default/files/2025-09/2026list_en_fin…
  19. World Anti-Doping Agency. Prohibited List 2027. International Standard, in force 1 January 2027; read 21 Nov 2026. www.wada-ama.org/sites/default/files/2026-11/2027list_en_fin…
  20. World Anti-Doping Agency. The Prohibited List (“The List is updated at least annually”; “If you cannot find a Substance or Method listed, please verify its status with your Anti-Doping Organization”). Web page, read 21 Nov 2026. www.wada-ama.org/en/prohibited-list

Plain-English summary of public sources, not legal or medical advice. Last checked 21 Nov 2026.

Questions

Is 5-amino-1MQ a peptide?

No. PubChem identifies 5-amino-1-methylquinolinium as a small molecule, not a peptide.

Is MOTS-c a small molecule?

No. MOTS-c is a 16-amino-acid peptide encoded in mitochondrial 12S rRNA.

Have both compounds been compared in a human study?

We found none. We also found no published study that gave either compound to people (PubMed and ClinicalTrials.gov, 21 November 2026); the human MOTS-c studies measured the body’s own levels.

Does WADA name both compounds?

The 2026 and 2027 Lists name MOTS-c in S4.4.1. Neither names 5-amino-1MQ; for a substance it does not list, WADA says “please verify its status with your Anti-Doping Organization”.

What do FDA’s databases list for 5-amino-1MQ?

Drugs@FDA (through openFDA, data to 20 November 2026) lists no product with it as an active ingredient, and FDA’s 503A nominations list (updated 14 May 2026) has no entry for it. These are dated searches, not legal conclusions.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page